ZIFF DAVIS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ZIFF DAVIS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.36B | Feb 26, 2024 |
| FY2023 | Dec 31, 2022 | $1.39B | Feb 26, 2024 |
| FY2021 | Dec 31, 2021 | $408.63M | Mar 15, 2022 |
| FY2021 | Sep 30, 2021 | $355.15M | Mar 15, 2022 |
| FY2021 | Jun 30, 2021 | $341.29M | Mar 15, 2022 |
| FY2021 | Mar 31, 2021 | $311.66M | Mar 15, 2022 |
| FY2021 | Dec 31, 2020 | $384.06M | Mar 15, 2022 |
| FY2021 | Sep 30, 2020 | $273.01M | Mar 15, 2022 |
| FY2021 | Jun 30, 2020 | $250.36M | Mar 15, 2022 |
| FY2021 | Mar 31, 2020 | $251.41M | Mar 15, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.45B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.40B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.36B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $1.39B | Feb 25, 2025 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $316.38M | Mar 1, 2018 |
| FY2017 | Sep 30, 2017 | $273.62M | Mar 1, 2018 |
| FY2017 | Jun 30, 2017 | $273.17M | Mar 1, 2018 |
| FY2017 | Mar 31, 2017 | $254.67M | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $251.84M | Mar 1, 2018 |
| FY2017 | Sep 30, 2016 | $210.12M | Mar 1, 2018 |
| FY2017 | Jun 30, 2016 | $211.80M | Mar 1, 2018 |
| FY2017 | Mar 31, 2016 | $200.50M | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | $204.82M | Mar 1, 2017 |
| FY2016 | Sep 30, 2015 | $178.70M | Mar 1, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $362.91M | Mar 15, 2022 |
| FY2021 | Sep 30, 2021 | $305.45M | Mar 15, 2022 |
| FY2021 | Jun 30, 2021 | $292.51M | Mar 15, 2022 |
| FY2021 | Mar 31, 2021 | $267.80M | Mar 15, 2022 |
| FY2021 | Dec 31, 2020 | $337.90M | Mar 15, 2022 |
| FY2021 | Sep 30, 2020 | $230.73M | Mar 15, 2022 |
| FY2021 | Jun 30, 2020 | $207.20M | Mar 15, 2022 |
| FY2021 | Mar 31, 2020 | $204.60M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $341.26M | Mar 1, 2021 |
| FY2020 | Sep 30, 2019 | $282.43M | Mar 1, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.35M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $63.05M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $41.50M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $63.76M | Feb 25, 2025 |
| FY2021 | Dec 31, 2021 | $360.51M | Mar 15, 2022 |
| FY2021 | Sep 30, 2021 | $42.57M | Mar 15, 2022 |
| FY2021 | Jun 30, 2021 | $15.72M | Mar 15, 2022 |
| FY2021 | Mar 31, 2021 | $77.92M | Mar 15, 2022 |
| FY2021 | Dec 31, 2020 | $58.09M | Mar 15, 2022 |
| FY2021 | Sep 30, 2020 | $60.88M | Mar 15, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $183.09M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $113.65M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $132.61M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $198.94M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $167.34M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $138.34M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $88.22M | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | $244.28M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $245.71M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $242.57M | Mar 1, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.96M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $67.37M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $68.86M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $74.09M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $78.87M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $57.15M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $44.65M | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | $48.37M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $46.00M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $38.05M | Mar 1, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $407.07M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $390.32M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $319.96M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $336.44M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $516.54M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $480.08M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $412.54M | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | $401.33M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $264.42M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $282.39M | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.20M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $106.64M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $108.73M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $106.15M | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $113.74M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $92.55M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $70.59M | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | $56.38M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $39.60M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $24.75M | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.66B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $3.70B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $3.47B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $3.53B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $3.77B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $3.67B | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $3.51B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $2.56B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $2.45B | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $2.06B | Mar 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.91B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.89B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.58B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $1.64B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $1.80B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $2.45B | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $2.19B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $1.53B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $1.43B | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.15B | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.75B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.81B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.89B | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $1.89B | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $1.97B | Feb 25, 2025 |
| FY2023 | Dec 31, 2020 | $1.21B | Feb 26, 2024 |
| FY2022 | Dec 31, 2019 | $1.31B | Mar 1, 2023 |
| FY2021 | Dec 31, 2018 | $1.04B | Mar 15, 2022 |
| FY2020 | Dec 31, 2017 | $1.02B | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | $914.54M | Mar 2, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.61B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.58B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.55B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $1.59B | Feb 25, 2025 |
| FY2023 | Dec 31, 2021 | $1.53B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $1.53B | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $1.31B | Mar 15, 2022 |
| FY2020 | Dec 31, 2018 | $1.38B | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $1.20B | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $1.12B | Mar 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.34B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.40B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.49B | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $1.54B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $1.52B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $809.11M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $891.53M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $769.58M | Mar 2, 2020 |
| FY2018 | Jan 1, 2018 | $724.66M | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | $723.06M | Mar 1, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $607.01M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $505.88M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $737.61M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | $652.79M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $694.84M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $176.44M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $575.62M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $209.47M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $350.95M | Mar 1, 2019 |
| FY2018 | Dec 31, 2016 | $123.95M | Mar 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $866.50M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $864.28M | Feb 24, 2026 |
| FY2023 | Dec 31, 2023 | $1.00B | Feb 26, 2024 |
| FY2023 | Dec 31, 2022 | $999.05M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $1.09B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.58B | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.45B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $1.01B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $1.00B | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $601.75M | Mar 1, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 25, 2025 |
| FY2021 | Dec 31, 2021 | 7 | Mar 15, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Mar 15, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Mar 15, 2022 |
| FY2021 | Mar 31, 2021 | 1 | Mar 15, 2022 |
| FY2021 | Dec 31, 2020 | 1 | Mar 15, 2022 |
| FY2021 | Sep 30, 2020 | 1 | Mar 15, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 25, 2025 |
| FY2021 | Dec 31, 2021 | 7 | Mar 15, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Mar 15, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Mar 15, 2022 |
| FY2021 | Mar 31, 2021 | 1 | Mar 15, 2022 |
| FY2021 | Dec 31, 2020 | 1 | Mar 15, 2022 |
| FY2021 | Sep 30, 2020 | 1 | Mar 15, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 38.38M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 42.85M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 46.08M | Feb 25, 2025 |
| FY2023 | Dec 31, 2022 | 47.27M | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | 47.44M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 44.35M | Mar 15, 2022 |
| FY2020 | Dec 31, 2019 | 47.65M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 47.48M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 47.85M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 47.44M | Mar 1, 2018 |